- Article
- Source: Campus Sanofi
- 23 Oct 2023
AUBAGIO® (teriflunomide): MoA and Safety - Prof. Patrick Vermersch
Prescribing Information can be found through the links at the Product Carousel on the bottom of the page.
Speaker:
Professor Patrick Vermersch, MD, PhD
University of Lille, France
Learning Objectives:
-
To understand the mechanism of action of AUBAGIO®
- To identify the safety and tolerability of AUBAGIO® from both clinical and post-marketing studies
- To recognise the role of AUBAGIO® can play in women with MS of childbearing potential who are on reliable contraception
Reflective learning guide and CPD certificate
.jpg)
Related Videos
22:45
AUBAGIO® (teriflunomide) Overview: Efficacy (Brain Health) and Real-World (Patient-Reported Outcomes, Adherence, Effectiveness) - Prof. Jiwon Oh
18:56
Preserving Brain Health | Part 1: Underlying Pathology of Chronic Smouldering MS - Prof. Gavin Giovannoni
19:17
Preserving Brain Health | Part 2: Clinical Progression and Smouldering Disease - Prof. Gavin Giovannoni
24:53
Preserving Brain Health | Part 3: Advanced Imaging Techniques in Routine Clinical Practice - Prof. Jiwon Oh
22:45
AUBAGIO® (teriflunomide) Overview: Efficacy (Brain Health) and Real-World (Patient-Reported Outcomes, Adherence, Effectiveness) - Prof. Jiwon Oh
18:56
Preserving Brain Health | Part 1: Underlying Pathology of Chronic Smouldering MS - Prof. Gavin Giovannoni
19:17
Preserving Brain Health | Part 2: Clinical Progression and Smouldering Disease - Prof. Gavin Giovannoni
24:53
Preserving Brain Health | Part 3: Advanced Imaging Techniques in Routine Clinical Practice - Prof. Jiwon Oh
Neurology Products
%20-%20Copy.png){kind=logo}
|
Prescribing Information GB MAT-XU-2200676 (v6.0) |
.png){kind=logo}
|
Prescribing Information GB MAT-XU-2200680 (v3.0) |
MAT-XU-2302954 (v1.0) Date of preparation: October 2023